Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis - PubMed (original) (raw)
Review
Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis
Marija Branković et al. Int J Mol Sci. 2022.
Abstract
The emerging issues nowadays are non-alcoholic fatty liver disease (NAFLD) and its advanced stage non-alcoholic steatohepatitis (NASH), which further can be a predisposing factor for chronic liver complications, such as cirrhosis and/or development of hepatocellular carcinoma (HCC). Liver lipotoxicity can influence the accumulation of reactive oxygen species (ROS), so oxidative stress is also crucial for the progression of NASH. Moreover, NASH is in strong connection with metabolic disorders, and supporting evidence shows that insulin resistance (IR) is in a close relation to NAFLD, as it is involved in the progression to NASH and further progression to hepatic fibrosis. The major issue is that, at the moment, NASH treatment is based on lifestyle changes only due to the fact that no approved therapeutic options are available. The development of new therapeutic strategies should be conducted towards the potential NAFLD and NASH treatment by the modulation of IR but also by dietary antioxidants. As it seems, NASH is going to be the leading indication for liver transplantation as a consequence of increased disease prevalence and the lack of approved treatment; thus, an effective solution is needed as soon as possible.
Keywords: NAFLD; NASH; lipids; liver; metabolism.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Scheme 1
Diagnosis, treatment, risk factors, and cardiovascular consequences of non-alcoholic steatohepatitis.
Figure 1
Liver biopsy of non-alcoholic steatohepatitis (NASH) stage 3 (severe fibrosis). Portal spaces are normal size or slightly dilated, connected by septa of connective tissue that sometimes surround parenchymal nodules. They are moderately to strongly infiltrated with lymphocytes and rare granulocytes. The parenchyma is partially nodularly transformed, and rare focal necrosis is present. Hepatocyte joists are focally thickened. Focal glycogenization of hepatocyte nuclei is present. Ballooned hepatocytes are numerous. Coarse-grained fatty change is diffuse. Kupffer cells multiply in the sinuses. There are numerous foci of perisinusoid necrosis. Hematoxylin and eosin (H&E) staining, 10 × Legend: 1, lymphocytes; 2, focal necrosis; 3, ballooned hepatocytes; 4, fat accumulation; 5, Kupffer cells.
Figure 2
NASH treatment options.
Similar articles
- Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants.
Rives C, Fougerat A, Ellero-Simatos S, Loiseau N, Guillou H, Gamet-Payrastre L, Wahli W. Rives C, et al. Biomolecules. 2020 Dec 21;10(12):1702. doi: 10.3390/biom10121702. Biomolecules. 2020. PMID: 33371482 Free PMC article. Review. - Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T, Goto T, Hirotsu Y, Masuzaki R, Moriyama M, Omata M. Kanda T, et al. Int J Mol Sci. 2020 Feb 23;21(4):1525. doi: 10.3390/ijms21041525. Int J Mol Sci. 2020. PMID: 32102237 Free PMC article. Review. - Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J. Wu J. Oncotarget. 2016 Jul 5;7(27):42762-42776. doi: 10.18632/oncotarget.8641. Oncotarget. 2016. PMID: 27072576 Free PMC article. Review. - Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
Wang K, Wei Y, Xu R, Li Y, Mao C. Wang K, et al. Adv Exp Med Biol. 2022;1372:157-168. doi: 10.1007/978-981-19-0394-6_11. Adv Exp Med Biol. 2022. PMID: 35503180 - Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S, Kienbacher C, Halilbasic E, Rechling C, Kazemi-Shirazi L, Hofer H, Munda P, Trauner M. Traussnigg S, et al. Dig Dis. 2015;33(4):598-607. doi: 10.1159/000375353. Epub 2015 Jul 6. Dig Dis. 2015. PMID: 26159280 Review.
Cited by
- Unveiling functionality and conducting two-sample mendelian randomization on WGCNA-identified oxidative stress-related hub genes in metabolic dysfunction-associated fatty liver disease.
Zhu Q, Liu J, Mei W, Zeng C. Zhu Q, et al. Biochem Biophys Rep. 2024 Sep 22;40:101829. doi: 10.1016/j.bbrep.2024.101829. eCollection 2024 Dec. Biochem Biophys Rep. 2024. PMID: 39376593 Free PMC article. - Spatial lipidomics reveals zone-specific hepatic lipid alteration and remodeling in metabolic dysfunction-associated steatohepatitis.
Seubnooch P, Montani M, Dufour JF, Masoodi M. Seubnooch P, et al. J Lipid Res. 2024 Sep;65(9):100599. doi: 10.1016/j.jlr.2024.100599. Epub 2024 Jul 18. J Lipid Res. 2024. PMID: 39032559 Free PMC article. - Misoprostol for non-alcoholic steatohepatitis: a randomised control trial.
Siyal M, Abbas Z, Qadeer MA, Saeed A, Ali U, Khatoon A. Siyal M, et al. BMJ Open Gastroenterol. 2024 Jun 6;11(1):e001342. doi: 10.1136/bmjgast-2023-001342. BMJ Open Gastroenterol. 2024. PMID: 38844374 Free PMC article. Clinical Trial. - Thrombospondin-2 as a potential noninvasive biomarker of hepatocyte injury but not liver fibrosis in children with MAFLD: A preliminary study.
Zdanowicz K, Flisiak-Jackiewicz M, Bobrus-Chociej A, Kowalczuk-Kryston M, Jamiolkowski J, Martonik D, Rogalska M, Lebensztejn DM. Zdanowicz K, et al. Clin Exp Hepatol. 2023 Dec;9(4):368-374. doi: 10.5114/ceh.2023.133108. Epub 2023 Nov 22. Clin Exp Hepatol. 2023. PMID: 38774195 Free PMC article. - Loss of SREBP-1c ameliorates iron-induced liver fibrosis by decreasing lipocalin-2.
Lee EH, Lee JH, Kim DY, Lee YS, Jo Y, Dao T, Kim KE, Song DK, Seo JH, Seo YK, Seong JK, Moon C, Han E, Kim MK, Ryu S, Shin M, Roh GS, Jung HR, Osborne TF, Ryu D, Jeon TI, Im SS. Lee EH, et al. Exp Mol Med. 2024 Apr;56(4):1001-1012. doi: 10.1038/s12276-024-01213-2. Epub 2024 Apr 16. Exp Mol Med. 2024. PMID: 38622198 Free PMC article.
References
- Chalasani N., Younossi Z., LaVine J.E., Charlton M., Cusi K., Rinella M., Harrison S.A., Brunt E.M., Sanyal A.J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–357. doi: 10.1002/hep.29367. - DOI - PubMed
- European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD) European Association for the Study of Obesity (EASO) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016;64:1388–1402. doi: 10.1016/j.jhep.2015.11.004. - DOI - PubMed
Publication types
MeSH terms
Grants and funding
This research received no external funding.
LinkOut - more resources
Full Text Sources
Medical
Research Materials